Apollomics, Inc. is a startup based in the United States, most recent round Series-c-plus.
Based in the United States, Apollomics, Inc. is a startup. Its most recent tracked round is Series-c-plus.
Apollomics, Inc. is a biotechnology company that discovers and develops oncology therapies, emphasizing combination treatments that harness the immune system and target specific molecular pathways. Its clinical-stage pipeline includes programs such as vebreltinib (APL-101), APL-102 and APL-501.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.